{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-286273","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2026-06-26T22:18:31+00:00","discovered_at":"2026-06-29T10:05:00.218391+00:00","generated_at":"2026-06-29T10:05:45.442250+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Viridian Therapeutics receives FDA approval for Lumvoa (veligrotug-vvze) to treat thyroid eye disease","bullets":["Lumvoa is the first FDA-approved treatment for TED with labeling covering both active and chronic disease.","Approval supported by positive Phase 3 THRIVE and THRIVE-2 trials meeting primary and all secondary endpoints.","Lumvoa showed statistically significant improvement in diplopia response and complete resolution in active and chronic TED.","Viridian plans to launch Lumvoa immediately with a comprehensive patient support program (ViridianCares).","Company will host a conference call on June 29, 2026, at 8:00 a.m. ET to discuss the approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-286273","json":"https://secwatch.observer/filing/0001193125-26-286273.json","markdown":"https://secwatch.observer/filing/0001193125-26-286273.md","text":"https://secwatch.observer/filing/0001193125-26-286273.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/0001193125-26-286273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/d164211d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T10:05:45.442250+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}